|  |
| --- |
| **Subtype-specific alterations in the serological autoantibody profile of open-angle glaucoma patients** |
| Vanessa M. Beutgen, Norbert Pfeiffer, Franz H. Grus |

Supplementary Data

**S2 Supplementary file 2:** Post hoc test of significant ANOVA results. HSD test for unequal N was applied. Tables show respective P values.

**Table S2 - 1** ANOVA post hoc test for MCM7. HSD for unequal N.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Group | Unequal N HSD; Variable: **MCM7** Marked (\*) differences are significant at p < .05000 | | | |
| |  | | --- | | {1} M=6.9070 | | |  | | --- | | {2} M=7.1808 | | |  | | --- | | {3} M=7.0444 | | |  | | --- | | {4} M=7.4336 | |
| |  | | --- | | NTG {1} | |  | 0,544786 | 0,909707 | 0,051964 |
| |  | | --- | | CTRL {2} | | 0,544786 |  | 0,855649 | 0,461392 |
| |  | | --- | | PEXG {3} | | 0,909707 | 0,855649 |  | 0,110207 |
| |  | | --- | | POAG {4} | | 0,051964 | 0,461392 | 0,110207 |  |

**Table S2 - 2** ANOVA post hoc test for HTRA2. HSD for unequal N.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Group | Unequal N HSD; Variable: **HTRA2** Marked (\*) differences are significant at p < .05000 | | | |
| |  | | --- | | {1} M=9.7078 | | |  | | --- | | {2} M=10.070 | | |  | | --- | | {3} M=9.5585 | | |  | | --- | | {4} M=9.8786 | |
| |  | | --- | | NTG {1} | |  | 0,333242 | 0,899597 | 0,857645 |
| |  | | --- | | CTRL {2} | | 0,333242 |  | \* 0,021893 | 0,714546 |
| |  | | --- | | PEXG {3} | | 0,899597 | \* 0,021893 |  | 0,287313 |
| |  | | --- | | POAG {4} | | 0,857645 | 0,714546 | 0,287313 |  |

**Table S2 - 3** ANOVA post hoc test for HSP27. HSD for unequal N.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Group | Unequal N HSD; Variable: **HSP27** Marked (\*) differences are significant at p < .05000 | | | |
| |  | | --- | | {1} M=12.015 | | |  | | --- | | {2} M=11.856 | | |  | | --- | | {3} M=12.369 | | |  | | --- | | {4} M=11.870 | |
| |  | | --- | | NTG {1} | |  | 0,873940 | 0,326848 | 0,899867 |
| |  | | --- | | CTRL {2} | | 0,873940 |  | \* 0,016657 | 0,999844 |
| |  | | --- | | PEXG {3} | | 0,326848 | \* 0,016657 |  | \* 0,023132 |
| |  | | --- | | POAG {4} | | 0,899867 | 0,999844 | \* 0,023132 |  |

**Table S2 - 4** ANOVA post hoc test for CRYGS. HSD for unequal N.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Group | Unequal N HSD; Variable: **CRYGS** Marked (\*) differences are significant at p < .05000 | | | |
| |  | | --- | | {1} M=13.745 | | |  | | --- | | {2} M=13.558 | | |  | | --- | | {3} M=14.192 | | |  | | --- | | {4} M=13.560 | |
| |  | | --- | | NTG {1} | |  | 0,789047 | 0,117142 | 0,794590 |
| |  | | --- | | CTRL {2} | | 0,789047 |  | \* 0,000860 | 0,999999 |
| |  | | --- | | PEXG {3} | | 0,117142 | \* 0,000860 |  | \* 0,001061 |
| |  | | --- | | POAG {4} | | 0,794590 | 0,999999 | \* 0,001061 |  |

**Table S2 - 5** ANOVA post hoc test for CLTA/B/C. HSD for unequal N.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Group | Unequal N HSD; Variable: **CLTA/B/C** Marked (\*) differences are significant at p < .05000 | | | |
| |  | | --- | | {1} M=11.166 | | |  | | --- | | {2} M=10.891 | | |  | | --- | | {3} M=8.6098 | | |  | | --- | | {4} M=11.235 | |
| |  | | --- | | NTG {1} | |  | 0,933870 | \* 0,000008 | 0,998844 |
| |  | | --- | | CTRL {2} | | 0,933870 |  | \* 0,000008 | 0,813021 |
| |  | | --- | | PEXG {3} | | \* 0,000008 | \* 0,000008 |  | \* 0,000008 |
| |  | | --- | | POAG {4} | | 0,998844 | 0,813021 | \* 0,000008 |  |



**Figure S2 - 1** Box plot of HTRA2 autoantibody levels in CTRL, NTG, PEXG & POAG.



**Figure S2 - 2** Box plot of HSP27 autoantibody levels in CTRL, NTG, PEXG & POAG.



**Figure S2 - 3** Box plot of CRYGS autoantibody levels in CTRL, NTG, PEXG & POAG.